Etanercept-induced myositis: Do We have to stop it? a surprising outcome

Hassan Tariq, Bibi Ayesha, Karen M. Weidenheim, Giovanni Franchin

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We discuss a case of a 47-year-old man who presented with progressive proximal muscle weakness of the upper and lower extremities and unstable gait. He had been on etanercept for 6 months for severe psoriasis and psoriatic arthritis with good control of his disease. Serum creatine kinase (CK) level was found to be 5666 U/L and muscle biopsy showed a marked inflammatory myopathic process likely secondary to etanercept. He was started on high-dose steroids and advised to discontinue etanercept. Despite our recommendation, he never stopped using etanercept due to fear of a psoriasis flare. Three months later, he had significant improvement of clinical symptoms, normalised serum CK levels and discontinued prednisone.

Original languageEnglish (US)
Article number213577
JournalBMJ Case Reports
Volume2016
DOIs
StatePublished - Jan 11 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Etanercept-induced myositis: Do We have to stop it? a surprising outcome'. Together they form a unique fingerprint.

  • Cite this